Matching articles for "tazarotene"
Issue 1712 · September 30, 2024
Drugs for Plaque Psoriasis

Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with…

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):153-60 doi:10.58347/tml.2024.1712a
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Issue 1712 · September 30, 2024
Comparison Table: Some Drugs for Plaque Psoriasis (online only)

View the Comparison Table: Some Drugs for Plaque Psoriasis

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):e160-6 doi:10.58347/tml.2024.1712b
View the Comparison Table: Some Drugs for Plaque Psoriasis
Issue 1695 · February 5, 2024
Drugs for Acne

Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.

Med Lett Drugs Ther. 2024 Feb 5; 66(1695):17-20 doi:10.58347/tml.2024.1695a
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Issue 1668 · January 23, 2023
Topical Roflumilast (Zoryve) for Plaque Psoriasis

The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):10-2 doi:10.58347/tml.2023.1668b
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa) , another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
Issue 1656 · August 8, 2022
Tapinarof Cream (Vtama) for Psoriasis

The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):122-4
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Issue 1640 · December 27, 2021
Clascoterone Cream (Winlevi) for Acne

The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor…

Med Lett Drugs Ther. 2021 Dec 27; 63(1640):202-4
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Issue 1612 · November 30, 2020
Drugs for Acne

Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of…

Med Lett Drugs Ther. 2020 Nov 30; 62(1612):188-91
Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of acne were last published in 2016.
Issue 1587 · December 16, 2019
Trifarotene (Aklief) - A New Topical Retinoid for Acne

The FDA has approved trifarotene 0.005% cream ( Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for…

Med Lett Drugs Ther. 2019 Dec 16; 61(1587):195-7
The FDA has approved trifarotene 0.005% cream ( Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for treatment of acne; tretinoin ( Retin-A , and others), adapalene ( Differin , and generics), and tazarotene ( Tazorac , and others) have been available by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment of acne in patients ≥12 years old.
Issue 1574 · June 17, 2019
Drugs for Psoriasis

Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.

Med Lett Drugs Ther. 2019 Jun 17; 61(1574):89-96
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.
Issue 1574 · June 17, 2019
Expanded Table: Some Drugs for Psoriasis (online only)

View the Expanded Table: Some Drugs for Psoriasis

Med Lett Drugs Ther. 2019 Jun 17; 61(1574):e96-103
View the Expanded Table: Some Drugs for Psoriasis
Issue 1573 · June 3, 2019
Risankizumab (Skyrizi) for Psoriasis

The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be…

Med Lett Drugs Ther. 2019 Jun 3; 61(1573):81-3
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Issue 1563 · January 14, 2019
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):4-6
Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Issue 1533 · November 6, 2017
Guselkumab (Tremfya) for Psoriasis

The FDA has approved the interleukin (IL)-23 blocker guselkumab ( Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):179-80
The FDA has approved the interleukin (IL)-23 blocker guselkumab ( Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.
Issue 1525 · July 17, 2017
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis

The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond…

Med Lett Drugs Ther. 2017 Jul 17; 59(1525):118-9
The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.
Issue 1494 · May 9, 2016
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis

The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic…

Med Lett Drugs Ther. 2016 May 9; 58(1494):59-60
The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is the second IL-17A antagonist to be approved for this indication in the US; secukinumab ( Cosentyx – Novartis) was the first.
Issue 1492 · April 11, 2016
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D 3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of…

Med Lett Drugs Ther. 2016 Apr 11; 58(1492):48-9
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D 3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Issue 1487 · February 1, 2016
Drugs for Acne

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Med Lett Drugs Ther. 2016 Feb 1; 58(1487):13-5
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promotes development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1476 · August 31, 2015
Onexton Gel for Acne

The FDA has approved another fixed combination of the antibiotic clindamycin phosphate and the oxidizing agent benzoyl peroxide (Onexton Gel 1.2%/3.75% – Valeant) for topical treatment of acne in patients…

Med Lett Drugs Ther. 2015 Aug 31; 57(1476):124
The FDA has approved another fixed combination of the antibiotic clindamycin phosphate and the oxidizing agent benzoyl peroxide (Onexton Gel 1.2%/3.75% – Valeant) for topical treatment of acne in patients ≥12 years old. Topical products containing the same drugs have been available for many years. Onexton Gel contains a new strength of benzoyl peroxide.
Issue 1470 · June 8, 2015
Drugs for Psoriasis

Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids.…

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):81-4
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
Issue 125 · January 1, 2013
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2013 Jan; 11(125):1-8
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1353 · December 13, 2010
Clindamycin-Tretinoin (Veltin Gel) for Acne

Veltin Gel (Stiefel), a fixed-dose combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025%, has been approved by the FDA for topical treatment of acne vulgaris in patients…

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):102-3
Veltin Gel (Stiefel), a fixed-dose combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025%, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old. Another product containing the same active ingredients (Ziana) has been on the market since 2006.
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Issue 1330 · January 25, 2010
Ustekinumab (Stelara) for Psoriasis

The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):7-8
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
Issue 1310 · April 20, 2009
Adapalene-Benzoyl Peroxide (Epiduo) for Acne

Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin) , a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):31-2
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin) , a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.
Issue 75 · November 1, 2008
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2008 Nov; 6(75):75-82
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 35 · July 1, 2005
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive…

Treat Guidel Med Lett. 2005 Jul; 3(35):49-56
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1159 · June 23, 2003
Blue light (ClearLight) for Acne Vulgaris

A high-intensity, narrow-band blue light ( ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review…

Med Lett Drugs Ther. 2003 Jun 23; 45(1159):50-1
A high-intensity, narrow-band blue light ( ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Issue 1154 · April 14, 2003
Alefacept (Amevive) For Treatment of Psoriasis

Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.

Med Lett Drugs Ther. 2003 Apr 14; 45(1154):31-2
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Issue 1132 · June 10, 2002
Tazarotene (Tazorac) for Acne

Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.

Med Lett Drugs Ther. 2002 Jun 10; 44(1132):52-3
Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.